Organization
German Cancer Research Center (DKFZ)
8 abstracts
Abstract
Cost-utility analysis of a supervised exercise program for patients with metastatic breast cancer in the PREFERABLE-EFFECT randomized controlled trial (RCT).Org: University Medical Center Utrecht, Julius Center for Health Sciences and Primary Care, Utrecht University, German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT) Heidelberg,
Abstract
Efficacy and safety of erdafitinib in pediatric patients with advanced solid tumors and FGFR alterations in the phase 2 RAGNAR trial.Org: Hopp Children’s Cancer Center Heidelberg (KiTZ), Heidelberg University Hospital and German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT), Memorial Sloan Kettering Cancer Center, FLENI,
Abstract
Use of chemotherapy and loco-regional therapy for stage IA triple-negative breast cancer and their association with oncologic outcomes: A cancer registry study.Org: National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany, Geschäftsstelle Qualitätskonferenzen bei der Klinischen Landesregisterstelle Baden-Württemberg GmbH, Krebsregister Baden-Württemberg, Stuttgart, Germany, Breast Cancer Center, Klinik St. Elisabeth, Heidelberg, Germany, Department of Obstetrics and Gynecology, University Hospital of Schleswig Holstein, Campus Lübeck, Lübeck, Germany, National Center for Tumor Diseases (NCT),
Abstract
3D volume growth rate evaluation in the EORTC-BTG-1320 clinical trial for recurrent WHO grade 2 and 3 meningiomas.Org: Aix-Marseille University CHU Timone, APHM, Service d'Oncologie Multidisciplinaire & Innovations Thérapeutiques, CNRS UMR 5309-INSERM U1209, INP, Inst Neurophysiopathol,
Abstract
Long-term survival with IDH wildtype glioblastoma: First results from the ETERNITY Brain Tumor Funders’ Collaborative Consortium (EORTC 1419).Org: University Hospital and University of Zurich, Institute of Neuropathology, University Hospital Düsseldorf, University of California, San Francisco, Division of Endocrinology, San Francisco, CA, University and City of Health and Science Hospital,
Abstract
LOGGIC/FIREFLY-2: A phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration.Org: Hopp Children’s Cancer Center Heidelberg (KiTZ), German Cancer Research Center (DKFZ), Children's National Hospital, Washington, DC, Seattle Children’s Hospital, Orlando Health Arnold Palmer Hospital for Children,
Abstract
Clinical evidence and benefit of special FDA designations in anti-cancer drugs.Org: DKFZ-Hector Cancer Institute and Department of Personalized Oncology, University Medical Center Mannheim, Division of Personalized Medical Oncology, German Cancer Research Center (DKFZ), German Center for Lung Research (DZL),
Abstract
Association of SARS-CoV-2 vaccinations and personal protective measures with seroconversion and risk of infection in a large real-world cohort of patients with cancer.Org: DKFZ-Hector Cancer Institute and Department of Personalized Oncology, University Medical Center Mannheim, Division of Personalized Medical Oncology, German Cancer Research Center (DKFZ), German Center for Lung Research (DZL),